| 5/24/2024 | IGPV | Roche acquisition of LumiraDX attracts regulatory attention
|
| 9/15/2022 | IG | Moody's raises Roche
|
| 2/6/2020 | CVIG | Moody’s changes Roche view to positive
|
| 12/31/2014 | IG | Market Commentary: Outlook 2015: High-grade primary’s momentum to continue into 2015; M&A drives activity
|
| 11/13/2014 | EMHYMUPFPV | Market Commentary: KfW, Roche, Citigroup issue bonds; supply tops $30 billion; Verizon, Bank of America firm
|
| 11/13/2014 | IG | Market Commentary: KfW, Roche, Citigroup issue bonds; supply tops $30 billion; Verizon, Bank of America firm
|
| 11/13/2014 | IG | New Issue: Roche prices $1 billion of notes in tranches due 2024, 2044
|
| 10/1/2014 | IG | Market Commentary: Bayer sells megadeal for purchase of Merck unit; CBL, Ares price; spreads generally ease
|
| 9/23/2014 | EMHYMUPFPV | Market Commentary: Sysco prices to overwhelming demand; ING Bank, Nordic Investment Bank price; spreads ease
|
| 9/23/2014 | IG | Market Commentary: Sysco prices to overwhelming demand; ING Bank, Nordic Investment Bank price; spreads ease
|
| 9/22/2014 | EMHYMUPFPV | Market Commentary: Roche prices $5.75 billion offering; Thomson Reuters, Niagara also price; spreads firm
|
| 9/22/2014 | IG | Market Commentary: Roche prices $5.75 billion offering; Thomson Reuters, Niagara also price; spreads firm
|
| 9/22/2014 | IG | New Issue: Roche Holding prices $5.75 billion of notes in six tranches
|
| 12/31/2013 | IG | Outlook 2014: High-grade primary issuance to decrease slightly in 2014 following record year
|
| 4/30/2013 | IG | Market Commentary: Apple brings record $17 billion deal, joins Boeing, RBC in primary; Apple notes trade tighter
|
| 1/31/2013 | CVIG | Fitch upgrades Roche
|
| 11/5/2012 | IG | Market Commentary: AbbVie prices huge deal after delay; Boardwalk Pipelines, Invesco sell; secondary sees volume
|
| 9/17/2012 | CV | S&P lifts Roche
|
| 9/7/2011 | CV | Moody's upgrades Roche
|
| 2/16/2011 | CV | Fitch ups Roche to positive
|
| 2/4/2010 | IG | Market Commentary: Kraft, Berkshire, Pacific Life sell nearly $18 billion in bonds; Kraft tighter in trading
|
| 1/22/2010 | IG | Market Commentary: Primary tone still poor, mix of deals seen in week ahead; financials off more; Dow, Roche lose
|
| 12/31/2009 | IG | Outlook 2010: Drug companies, money managers lead 2009's notable deals
|
| 3/27/2009 | IG | Moody's lowers Roche, keeps Genentech on review
|
| 3/26/2009 | SS | Roche completes tender offer for Genentech
|
| 3/17/2009 | IG | Market Commentary: Pfizer sells $13.5 billion bond issue; State Street, SoCal Edison price; Pfizer bonds tighten
|
| 3/13/2009 | CVIG | Fitch downgrades Roche
|
| 3/12/2009 | SS | Market Commentary: Genentech OKs latest bid; bidding war on way for CV Therapeutics; CF Industries pushes for Terra deal
|
| 3/9/2009 | SS | Market Commentary: Merck plows over Schering-Plough; Dow, Rohm & Haas settle; Genentech wants more from Roche
|
| 3/6/2009 | SS | Roche increases per-share offer price for Genentech to $93 in effort to close deal
|
| 3/6/2009 | SS | Market Commentary: Roche ups bid for Genentech; Rohm & Haas investors bank on talks; Whole Foods readies for competition
|
| 3/2/2009 | SS | Market Commentary: NRG buy of Reliant assets may slow down Exelon; IPC takes out Max; traders brace for Dow to hit 6,000
|
| 2/23/2009 | IG | Market Commentary: HP, Baxter, Waste Management, Western Union, Arizona Public sell bonds; new issues see little gain
|
| 2/23/2009 | SS | Genentech rejects Roche's tender offer, urges shareholders to do the same
|
| 2/20/2009 | IG | Market Commentary: High-grade market takes beating on bank rumors; Roche bonds lose steam, Citi, Bank of America lower
|
| 2/19/2009 | IG | New Issue: Roche gives terms for upsized $16 billion notes in six tranches
|
| 2/19/2009 | IG | Market Commentary: New Roche bonds trade solidly higher; Snap-on prices two-part deal; CBS gains on debt-payment pledge
|
| 2/18/2009 | IG | New Issue: Roche sells upsized $16 billion notes in six tranches
|
| 2/18/2009 | IG | Market Commentary: Roche sells mega deal, Canadian National Rail, Goodrich also price; DuPont new bonds widen
|
| 2/17/2009 | IG | Roche plans multi-tranche note offering expected to total $8 billion
|
| 2/17/2009 | IG | Market Commentary: Honeywell, Union Pacific, Coca-Cola Enterprises, DuPont sell bonds, Roche plans large deal; fears send banks wider
|
| 2/10/2009 | SS | Market Commentary: Market frowns on Ticketmaster union; investors want higher Genentech bid; SiRF buyout gives best option
|
| 2/9/2009 | SS | Market Commentary: Biogen ripe for $76-a-share buyout; Genentech buyout bid opens; Rohm & Haas pressures Dow Chemical
|
| 2/9/2009 | SS | Roche begins tender offer for Genentech
|
| 1/30/2009 | SS | Roche plans cash tender offer for Genentech shares; Genentech urges shareholders to hold off
|
| 1/30/2009 | SS | Market Commentary: Genentech bid lacks support; Wyeth buyout includes hefty breakup fees; Exelon moves for NRG control
|
| 1/27/2009 | SS | Market Commentary: Roche bid for Genentech predicted to increase; CV not likely to bite at Astellas offer, analyst says
|
| 1/13/2009 | SS | Market Commentary: Elan moves closer to sale block; second bid for Genentech expected; Puget trades at discount to deal
|
| 1/2/2009 | SS | Roche completes tender offer for Memory Pharmaceuticals
|
| 11/25/2008 | SS | Roche to buy Memory Pharmaceuticals for $50 million
|
| 8/13/2008 | SS | Market Commentary: eBay bids for Gmarket; Longs jumps on CVS offer; Genetech spurns Roche offer
|
| 8/13/2008 | SS | Genentech says 'no' to Roche's plan to take control
|
| 7/25/2008 | SS | Market Commentary: Cleveland-Cliffs moves higher, possibly signaling arbs' expectation of sale
|
| 7/21/2008 | SS | Market Commentary: Yahoo!, Icahn settle proxy fight; Roche puts up $43.7 billion for Genentech; private equities try TransAlta
|
| 7/21/2008 | SS | Roche offers $43.7 billion for full control of Genentech
|
| 2/19/2008 | SS | Roche to close acquisition of Ventana Medical Systems
|
| 2/8/2008 | SS | Roche begins subsequent offer for Ventana shares
|
| 1/31/2008 | SS | Roche set to close offer for Ventana
|
| 1/22/2008 | SS | Market Commentary: B of A, Countrywide still seen on track; Roche to buy Ventana; Quebecor files; Ambac hunts for cash
|
| 1/22/2008 | SS | Roche increases offer for Ventana, companies enter merger agreement
|
| 1/16/2008 | SS | Roche extends tender offer for Ventana to March
|
| 11/14/2007 | SS | Market Commentary: Delta, United Airlines merger rumors lift shares; United Rentals shares dive; Qualcomm shares up
|
| 11/13/2007 | SS | Roche begins due diligence in bid for Ventana
|
| 10/29/2007 | SS | Roche tender offer for Ventana now expected to end in January
|
| 9/19/2007 | SS | Roche once again extends tender offer for Ventana
|
| 7/26/2007 | SS | Roche extends its 'full and fair' tender offer for Ventana
|
| 7/11/2007 | SS | Ventana rejects Roche's 'full and fair' offer, advises stockholders to withhold shares
|
| 6/27/2007 | CV | S&P: Roche unchanged
|
| 6/27/2007 | SS | Roche begins tender offer for Ventana
|
| 6/26/2007 | SS | Roche Diagnostics completes acquisition of BioVeris
|
| 6/25/2007 | SS | Roche makes bid for Ventana
|
| 4/4/2007 | SS | Roche to acquire BioVeris for $21.50 per share in $600 million transaction
|
| 10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
| 9/26/2006 | BT | Sareum, Roche to accelerate cancer drug research
|
| 9/18/2006 | BT | Roche, GlaxoSmithKline: Study shows women more likely to stay on Boniva for osteoporosis
|
| 9/8/2006 | BT | RBC analyst says in-vitro diagnostics market grew 7.5% in Q2
|
| 9/7/2006 | BT | Roche, Trimeris extend research agreement for Fuzeon HIV fusion inhibitor
|
| 9/5/2006 | BT | Roche seeks re-examination of CHMP opinion on Tarceva in pancreatic cancer
|
| 9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
| 8/30/2006 | BT | PDL: Roche no longer co-developing daclizumab in asthma, will collaborate on other indications
|
| 8/30/2006 | BT | Fitch lifts Roche view to positive
|
| 8/30/2006 | BT | Market Commentary: AnorMED snubs Genzyme bid; PDL higher as Roche backs out; Vasogen zooms 42%; Adeza up
|
| 8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
| 8/14/2006 | BT | Roche, Trimeris say Fuzeon supported for use in HIV therapy
|
| 7/31/2006 | BT | Roche's phase 3 colorectal cancer trial meets endpoints
|
| 7/28/2006 | BT | Roche receives negative opinion from European Committee for pancreatic cancer treatment Tarceva
|
| 7/26/2006 | BT | RBC makes Whistle Stop Tour at AACC
|
| 7/19/2006 | BT | Roche pays €56 million for Ipsen's diabetes medicine
|
| 7/18/2006 | BT | Emisphere, Roche sign multi-product research agreement
|
| 7/17/2006 | BT | Roche: Phase 3 studies show anti-anemia drug maintained hemoglobin levels in dialysis patients
|
| 7/11/2006 | BT | Roche's MabThera approved in Europe as maintenance therapy in lymphoma
|
| 6/26/2006 | BT | Roche, Trimeris phase 3 study data shows immune system benefits of Fuzeon HIV fusion inhibitor
|
| 6/21/2006 | BT | Evotec, Roche form alliance to discover new drugs to treat central nervous diseases
|
| 6/20/2006 | BT | Bear Stearns gives Roche outperform rating
|
| 6/7/2006 | BT | Roche: Xeloda plus cisplatin effective in treatment of advanced gastric cancer
|
| 6/6/2006 | BT | Aspreva, Roche receive orphan-drug designation for CellCept in rare autoimmune disease
|
| 5/24/2006 | BT | Roche, Entelos to collaborate in metabolic disease research
|
| 5/23/2006 | BT | Roche, Genentech: Recruitment to resume in Avastin phase 3 trial in early stage colon cancer
|
| 5/23/2006 | BT | Roche interim results show Pegasys plus Copegus sustained virologic response in treatment of hepatitis C
|
| 5/9/2006 | BT | ITC to investigate Amgen's complaint against Roche's Peg-EPO
|
| 5/8/2006 | BT | Roche acquires Borean Pharma's cardiovascular drug candidate Trimeric Apo A-I
|
| 5/1/2006 | BT | Roche says hepatitis C studies yield promising results for R1626 and Pegasys
|
| 4/26/2006 | BT | CuraGen, Roche Diagnostics launch updated version of the Genome Sequencer 20 System
|
| 4/20/2006 | BT | Roche applies to FDA to market C.E.R.A. for treatment of renal anemia
|
| 4/11/2006 | BT | Amgen asks trade commission to block import of peg-EPO by Roche
|
| 3/28/2006 | BT | Galapagos, Roche enter three-year collaboration
|
| 3/17/2006 | BT | New Roche, GlaxoSmithKline study shows women with osteoporosis say Boniva is more convenient
|
| 3/1/2006 | BT | MorphoSys, Roche expand therapeutic antibody partnership
|
| 2/28/2006 | BT | Memory, Roche expand deal to develop nicotine alpha-7 agonists
|
| 2/21/2006 | BT | Trimeris, Hoffman-LaRoche extend joint research agreement by one year
|
| 2/16/2006 | BT | Roche asks European regulators to approve early-stage breast-cancer drug Herceptin
|
| 2/13/2006 | BT | Roche, Applied Biosystems settle litigation with Bio-Rad Laboratories
|
| 2/1/2006 | BT | S&P rates Roche AA+
|
| 2/1/2006 | BT | Moody's assigns Roche Aa1
|
| 1/30/2006 | BT | Roche grants Epigenomics full rights to Tamoxifen treatment test
|
| 1/25/2006 | BT | Roche plans clinical trial with MorphoSys' HuCAL-derived Alzheimer antibody
|
| 1/23/2006 | BT | Roche, GlaxoSmithKline get FDA committee support for over-the-counter orlistat for weight loss
|
| 1/17/2006 | BT | Trimeris, Roche unveil two HIV fusion inhibitor drug candidates
|
| 1/9/2006 | BT | Evotec licenses Roche phase 1 compounds to treat Alzheimer's
|
| 1/6/2006 | BT | FDA approves Roche, GlaxoSmithKline's Boniva, first intravenous treatment for postmenopausal osteoporosis
|
| 1/3/2006 | BT | Aspreva, Roche win orphan status for CellCept to treat myasthenia gravis
|
| 1/3/2006 | BT | Roche's cardiac diagnostic assay cleared for additional indication
|
| 12/19/2005 | BT | Roche, Trimeris' Fuzeon boosts viral suppression of protease inhibitor in study
|
| 12/16/2005 | BT | Roche's CERA alleviates anemia in phase 3 studies
|
| 12/15/2005 | BT | Maxygen, Roche to co-develop recombinant factor VIIa therapeutics for acute bleeding
|
| 12/13/2005 | BT | Roche files IND for antibody developed in collaboration with Genmab
|
| 12/7/2005 | BT | Jefferies maintains Roche at buy
|
| 11/30/2005 | BT | Roche gets BioCryst license to help develop, commercialize BCX-4208
|
| 11/30/2005 | BT | Market Commentary: Adams secondary launched; Isis off; Durect up; Inspire, BioCryst rocket up; Merck bonds weaker
|
| 11/23/2005 | BT | Roche, Trimeris receive FDA approvable letter for use of Fuzeon with needle-free injection device
|
| 11/18/2005 | BT | Market Commentary: Onyx gains after 'well-priced' deal; Elan, Biogen rise; Protein Design Labs up; Cubist higher
|
| 11/17/2005 | BT | Market Commentary: Gilead off on reports of deaths; Onyx deal at bat; Durect rises on upgrade, but some buyers hesitate
|
| 11/16/2005 | BT | Gilead Sciences, Roche end Tamiflu dispute
|
| 11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
| 11/14/2005 | BT | Roche's CERA stabilizes anemia in renal patients not on dialysis, study shows
|
| 11/11/2005 | BT | Roche says study shows Pegasys plus Copegus reduces viral levels in hepatitis C patients
|
| 11/3/2005 | BT | Roche expands Pegasys study for hepatitis C treatment in Latinos
|
| 11/1/2005 | BT | Roche, Protein Design Labs expand deal to develop daclizumab
|
| 10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
| 10/24/2005 | BT | Market Commentary: Roche, Gilead gain on flu talks; niche flu names higher as well; Schering, Wyeth, Pfizer watched
|
| 10/20/2005 | BT | Roche agrees to sublicense Tamiflu to increase production over avian flu fears
|
| 10/17/2005 | BT | Innogenetics, Roche sign $27.5 million licensing deal
|
| 7/22/2005 | BT | Roche kept by Merrill at market overweight
|
| 7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
| 6/29/2005 | CV | Market Commentary: CV Therapeutics' new deal gains, supporting biotechs; Mirant trades in heavy volume; General Mills eases
|
| 6/29/2005 | BT | Market Commentary: CV Therapeutics, Lonza upsize convertibles, both higher in trade; Millennium gains on new CEO
|
| 4/26/2004 | CV | Market Commentary: OSI Pharma skyrockets amid buying frenzy as stock shoots up 139%; 4 new deals emerge
|
| 8/26/2003 | CV | Market Commentary: Mixed bag, as convertibles track stocks in another slow session; Xerox issue soars on dividend
|
| 7/23/2003 | CV | Deutsche pitches Roche euro 0% convert due 2021 on positive earnings
|
| 6/26/2003 | CV | Roche 0% convert due 2021 offers cheap volatility: Deutsche analysts
|
| 9/10/2002 | CV | Market Commentary: Market stalls on terrorist alert in advance of attack anniversary
|
| 8/19/2002 | CV | Market Commentary: OSI, ImClone wounded; retailers build on strong surge at Lowe's
|
